CRL vs. EXEL: Charles River Laboratories vs. Exelixis Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Exelixis (EXEL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while EXEL is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Exelixis (EXEL) is defensive at 0.41 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Exelixis (EXEL) at 44.32% sits in the top ROE quartile, while Charles River Laboratories (CRL) at 1.27% is closer to the peer norm — stronger capital efficiency for EXEL.

Exelixis (EXEL) at 35.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

Both Charles River Laboratories (CRL) at 23.42% and Exelixis (EXEL) at 40.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Exelixis (EXEL) at 6.98% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Exelixis (EXEL) at 57.95% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.

Exelixis (EXEL) at 0.09 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Charles River Laboratories (CRL) nor Exelixis (EXEL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Charles River Laboratories (CRL) nor Exelixis (EXEL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Exelixis (EXEL) at 6.80 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Charles River Laboratories (CRL) at 5.01 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.

Valuation Metrics